← Back
SAN FREDIANO
December, 05th | 13:15 - 14:00
FREE PAPERS - HIGHLIGHTED NEW DRUGS DME
Add to calendar
Chairs: KITCHENS JOHN, LUPIDI MARCO, PARRAVANO MARIACRISTINA
December, 05th | 13:15 - 13:18
Immune response of muller cells under diabetic conditions: the jak-stat signaling pathway as a potential new target
MUNK MARION
Add to calendar
Immune response of muller cells under diabetic conditions: the jak-stat signaling pathway as a potential new target
MUNK MARION
Add to calendar
December, 05th | 13:18 - 13:21
Clinical impact of oct-a images enhanced by a newly developed ai denoising program for retinal vascular visualization.
CHEUNG GEMMY
Add to calendar
Clinical impact of oct-a images enhanced by a newly developed ai denoising program for retinal vascular visualization.
CHEUNG GEMMY
Add to calendar
December, 05th | 13:21 - 13:24
Brolucizumab for the treatment of proliferative diabetic retinopathy: 54-week results from the condor study
WOLF SEBASTIAN
Add to calendar
Brolucizumab for the treatment of proliferative diabetic retinopathy: 54-week results from the condor study
WOLF SEBASTIAN
Add to calendar
December, 05th | 13:24 - 13:27
Faricimab in dme: results from the rhone-x long-term extension trial
PEARCE IAN
Add to calendar
Faricimab in dme: results from the rhone-x long-term extension trial
PEARCE IAN
Add to calendar
December, 05th | 13:27 - 13:30
Global real-world clinical and anatomical outcomes with faricimab in treatment-naïve patients with neovascular age-related macular degeneration or diabetic macular edema from a multi-country prospective non-interventional study: the voyager study
PARRAVANO MARIACRISTINA
Add to calendar
Global real-world clinical and anatomical outcomes with faricimab in treatment-naïve patients with neovascular age-related macular degeneration or diabetic macular edema from a multi-country prospective non-interventional study: the voyager study
PARRAVANO MARIACRISTINA
Add to calendar
December, 05th | 13:30 - 13:33
Indirect comparison of the relative effectiveness of faricimab vs aflibercept 8 mg in diabetic macular edema (dme) and neovascular age-related macular degeneration (namd)
LUPIDI MARCO
Add to calendar
Indirect comparison of the relative effectiveness of faricimab vs aflibercept 8 mg in diabetic macular edema (dme) and neovascular age-related macular degeneration (namd)
LUPIDI MARCO
Add to calendar
December, 05th | 13:33 - 13:36
48 week results from the helios phase 1 trial evaluating intravitreal otx-tki for non-proliferative diabetic retinopathy
DHOOT DILSHER
Add to calendar
48 week results from the helios phase 1 trial evaluating intravitreal otx-tki for non-proliferative diabetic retinopathy
DHOOT DILSHER
Add to calendar
December, 05th | 13:36 - 13:39
Port delivery system with ranibizumab (pds) for continuous treatment in dme and dr: 2-year data from the phase 3 pagoda and pavilion trials
KITCHENS JOHN
Add to calendar
Port delivery system with ranibizumab (pds) for continuous treatment in dme and dr: 2-year data from the phase 3 pagoda and pavilion trials
KITCHENS JOHN
Add to calendar
